Chronic myeloid leukemia (CML) comprises ~15 to 20% of all adult leukemias and the development of oral BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs) has revolutionized management. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.